Health care resource utilization and health care costs among digital weight-loss intervention participants and nonparticipants

IF 4.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Obesity Pub Date : 2025-08-14 DOI:10.1002/oby.24337
Casey Tak, Paige Thompson, Jessica L. Morse, Meaghan McCallum
{"title":"Health care resource utilization and health care costs among digital weight-loss intervention participants and nonparticipants","authors":"Casey Tak,&nbsp;Paige Thompson,&nbsp;Jessica L. Morse,&nbsp;Meaghan McCallum","doi":"10.1002/oby.24337","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective of this study was to compare health care resource utilization (HRU), health care costs, and glucagon-like peptide-1 (GLP-1) agonist use among working US adults who engaged in Noom Weight, a smartphone-based lifestyle intervention for weight management, to individuals offered Noom who did not enroll.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Insurance claims data were used to conduct retrospective analyses of 723 Noom participants matched via propensity scores and compared to 723 non-Noom participants at 6 months post index.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared to nonparticipants, Noom participants had significantly lower HRU, medical and pharmacy costs, and GLP-1 agonist use in the 6-month post-index period. On average, Noom participants had 3.2 fewer outpatient visits, 0.34 fewer emergency department visits, 0.25 fewer inpatient visits, and 0.012 fewer surgeries than non-Noom participants (all <i>p</i> values &lt;0.001). Noom participants’ health care costs were $831 lower than non-Noom participants. Relative to non-Noom users, Noom participants also had 42% fewer claims for GLP-1 agonists (<i>p</i> = 0.02).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Compared to matched nonparticipants, Noom participation was associated with lower HRU, health care costs, and GLP-1 agonist use at 6 months post index. Results of this study support Noom as a cost-effective and HRU-lowering digital weight-management program for working adults in the United States.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 9","pages":"1637-1644"},"PeriodicalIF":4.7000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24337","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24337","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The objective of this study was to compare health care resource utilization (HRU), health care costs, and glucagon-like peptide-1 (GLP-1) agonist use among working US adults who engaged in Noom Weight, a smartphone-based lifestyle intervention for weight management, to individuals offered Noom who did not enroll.

Methods

Insurance claims data were used to conduct retrospective analyses of 723 Noom participants matched via propensity scores and compared to 723 non-Noom participants at 6 months post index.

Results

Compared to nonparticipants, Noom participants had significantly lower HRU, medical and pharmacy costs, and GLP-1 agonist use in the 6-month post-index period. On average, Noom participants had 3.2 fewer outpatient visits, 0.34 fewer emergency department visits, 0.25 fewer inpatient visits, and 0.012 fewer surgeries than non-Noom participants (all p values <0.001). Noom participants’ health care costs were $831 lower than non-Noom participants. Relative to non-Noom users, Noom participants also had 42% fewer claims for GLP-1 agonists (p = 0.02).

Conclusions

Compared to matched nonparticipants, Noom participation was associated with lower HRU, health care costs, and GLP-1 agonist use at 6 months post index. Results of this study support Noom as a cost-effective and HRU-lowering digital weight-management program for working adults in the United States.

Abstract Image

数字减肥干预参与者和非参与者的卫生保健资源利用和卫生保健成本。
目的:本研究的目的是比较从事Noom体重(一种基于智能手机的体重管理生活方式干预)的美国工作成年人与未参加Noom的个体之间的卫生保健资源利用率(HRU)、卫生保健成本和胰高血糖素样肽-1 (GLP-1)激动剂的使用情况。方法:采用保险索赔数据对723名Noom参与者进行回顾性分析,并在指数后6个月与723名非Noom参与者进行比较。结果:与非参与者相比,Noom参与者在指数后6个月的HRU、医疗和药房费用以及GLP-1激动剂的使用显著降低。平均而言,与非Noom参与者相比,Noom参与者的门诊就诊次数减少3.2次,急诊科就诊次数减少0.34次,住院就诊次数减少0.25次,手术次数减少0.012次(所有p值均为p值)。结论:与匹配的非参与者相比,Noom参与者在指数后6个月的HRU、医疗费用和GLP-1激动剂使用均较低。这项研究的结果支持Noom作为一个具有成本效益和降低hru的数字体重管理程序在美国的工作成年人。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Obesity
Obesity 医学-内分泌学与代谢
CiteScore
11.70
自引率
1.40%
发文量
261
审稿时长
2-4 weeks
期刊介绍: Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信